

UC Riverside

UC Riverside Previously Published Works

Title

Network analysis of unstructured EHR data for clinical research.

Permalink

<https://escholarship.org/uc/item/1gh391sc>

Authors

Bauer-Mehren, Anna
Lependu, Paea
Iyer, Srinivasan V
et al.

Publication Date

2013

Peer reviewed

Network analysis of unstructured EHR data for clinical research

Anna Bauer-Mehren (PhD), Paea LePendou (PhD), Srinivasan V Iyer, Rave Harpaz (PhD),
Nicholas J Leeper (MD), and Nigam H Shah (MBBS, PhD)

Stanford University, Stanford, CA, USA

Abstract

In biomedical research, network analysis provides a conceptual framework for interpreting data from high-throughput experiments. For example, protein-protein interaction networks have been successfully used to identify candidate disease genes. Recently, advances in clinical text processing and the increasing availability of clinical data have enabled analogous analyses on data from electronic medical records. We constructed networks of diseases, drugs, medical devices and procedures using concepts recognized in clinical notes from the Stanford clinical data warehouse. We demonstrate the use of the resulting networks for clinical research informatics in two ways—cohort construction and outcomes analysis—by examining the safety of cilostazol in peripheral artery disease patients as a use case. We show that the network-based approaches can be used for constructing patient cohorts as well as for analyzing differences in outcomes by comparing with standard methods, and discuss the advantages offered by network-based approaches.

Introduction

Data mining of electronic health records (EHRs) is on the rise due to increasing availability of the data as well as to advances in clinical text processing¹⁻³. EHR mining has been used for detecting adverse drug event associations⁴⁻⁶ and for profiling off-label use of drugs⁷, among other uses^{8,9}. Simultaneously, in bioinformatics research, network analysis has provided the conceptual framework to interpret protein-protein interaction, gene-disease association and drug-target associations. For example, network analysis of protein-protein associations led to the identification of candidate genes for inherited Ataxias¹⁰, and revealed clusters of highly interacting proteins of functional relevance¹¹. Similarly, EHRs can be used to construct a large-scale network representation of associations among clinical entities. For example, a network representation of disease associations learned from clinical problem summary lists has been used to uncover unexpected associations¹² and a network representation of patients based on their associated ICD9 codes has been used for patient stratification¹³. Both types of networks have even been combined, for instance the integration of cellular networks with comorbidity networks constructed from Medicare data could generate hypotheses about disease mechanisms¹⁴.

However, most approaches are restricted to associations among drugs and diseases, and are based on the structured clinical data. In contrast with existing uses of network analysis in EHR mining, we construct networks from the unstructured clinical text and we include medical devices and procedures in addition to drugs and diseases. We hypothesize that we can use the resulting networks for accurate control group construction and outcomes analysis. In particular, we apply our network-based approaches to examine the safety of cilostazol in peripheral artery disease (PAD) patients, and we compare our results with standard methods used in comparative effectiveness research. We believe that network analysis offers ways to visualize and analyze associations mined from EHRs, which can provide novel insights into the data by taking into account the connectivity of the clinical events and entities.

Methods

Data Collection and Processing: We used data from the Stanford Translational Research Integrated Database Environment (STRIDE), which spans 17-years of data from 1.7 million patients with over 10.5 million unstructured clinical notes. We processed the clinical notes as described previously⁶. In brief, we used an optimized version of the NCBO Annotator^{3,6} with a set of 19 clinically relevant ontologies, removed ambiguous terms¹⁵⁻¹⁸, and flagged negated terms and terms attributed to family history^{19,20}. We normalized all drugs to their ingredients using RxNorm, such that the terms “pletal” and “cilostazol” are both normalized to the ingredient “cilostazol.” In addition, we made use of the hierarchies of the ontologies to aggregate concepts. More details on the data processing can be found in²¹.

Study and control group construction: Using the timestamp of the clinical note in which the treatment concept (cilostazol) was first mentioned, we defined an index time point of treatment for all patients and grouped the annotations into two groups: concepts associated with clinical events that happened before treatment (which can be used for matching control groups) and concepts associated with events that happened after treatment (which can be interpreted as outcomes). We defined a cohort of 11,547 PAD patients using the expert-selected concepts listed in Table 1. To reduce bias introduced by difference in

Table 1: Peripheral artery disease definition

Concept	UMLS CUI
Peripheral arterial diseases	C1704436
Peripheral vascular diseases	C0085096
Peripheral arterial occlusive disease	C1306889
Intermittent claudication	C0021775
Claudication (finding)	C1456822

data coverage, we excluded patients having less than one year's worth of data after their first PAD mention, reducing the number of PAD patients to 5,746. For the cilostazol study group, we selected 223 PAD patients who had a cilostazol mention after or at the same time as their first PAD mention.

Propensity score matching (PSM): We used PSM to address biases introduced by confounding variables. We manually defined 15 potential confounders including demographic variables such as gender, race, age at the first PAD mention, and co-morbidities as well as co-prescriptions. All covariates except for the demographic variables were defined by the first mention of the respective concept before the index time point. We used the Matching package for R²² to perform PSM and to check balance in the variables between the cilostazol and control groups.

Patient-patient similarity: We used all concepts before the index time point and constructed a patient-feature matrix, where each row represents a patient and each column a concept. The cells indicate the presence or absence of the concept in any clinical note before the index time point. To reduce dimensionality, we used the Human Disease Ontology to aggregate disease concepts and SNOMED CT to aggregate procedures. For drugs, we used the ATC hierarchy to group drugs into classes at the third level (therapeutic subgroup). We used the patient-feature matrix to compute pairwise patient similarity (s_p) using Jaccard index and visualized the resulting patient-patient similarity matrix as a network using Cytoscape²³. We then applied 1:1 nearest neighbor matching to construct a control group.

Outcome analysis: For analyzing the outcomes of patients, we used only the concepts after the index time point.

Logistic regression analysis: We defined a set of 9 expert-selected outcome variables. These outcome variables include major adverse cardiovascular events (MACE), major limb events (MALE) and cardiac arrhythmias. We computed odds ratios and 95% confidence intervals using logistic regression.

Concept-concept association network: We used co-occurrence statistics (Equation 1) to compute the association (s_c) between different concepts ($cid1, cid2$) from the clinical notes. We filtered scores based on the strength ($s_c \geq 2$) and significance ($p \leq 0.05$, one-sided Fisher's exact test) of the association. The nodes in the networks represent the clinical concepts (drugs, diseases, devices and procedures) and the edges their associations. We used associations between concepts for the cilostazol and control groups separately to construct a network for each group. To compare the outcomes in the cilostazol group with those in the control group, we merged the two concept-concept networks and only kept those nodes and edges that are over or under-represented in the cilostazol group compared to the control ($p \leq 0.05$, one-sided Fisher's exact test). We then visualized the resulting network using Cytoscape.

Equation 1

$$s_c(cid1, cid2) = \frac{P(cid1, cid2)}{P(cid1)P(cid2)}$$

Results

Our results show that network-based methods are at par with standard methods in comparative effectiveness research in terms of control group construction and analysis of clinical outcomes for the case of cilostazol use for PAD. PAD is a major health problem affecting millions of patients worldwide. It is defined by obstruction of infra-renal aorta and lower-extremity arteries leading to claudication and leads to a significant impairment of quality of life. Cilostazol is the most effective treatment for PAD and has a black-box warning for cardiovascular events, especially in patients with congestive heart failure due to prior experience with a similar drug²⁴.




Figure 1: (A) Patient-patient similarity network for constructing a control group and (B) outcome analysis based on network-based control group (similarity) and propensity-score matched control group (psm).

Control group construction: Figure 1A shows a network representation of the 223 cilostazol patients (red nodes) and their most similar PAD patients ($s_p \geq 0.36$). The thickness of the edges corresponds to the similarity between patients. Patients who share multiple disease, drug, device and procedure annotations are similar and thus closer in the network. We constructed a control group of 223 patients by choosing the nearest neighbor (1:1 match) or most similar patient (blue nodes) for each cilostazol patient. We also applied PSM on 15 expert-selected variables (potential confounders) such as age, gender, several co-morbidities and co-prescriptions.

Comparing the cilostazol group with all other PAD patients (before matching), we observe a significant difference or *imbalance* in several variables including gender (there are more males in the cilostazol group), co-prescriptions (cilostazol patients are taking more drugs), vascular surgical and bypass procedures (cilostazol patients undergo more procedures) (Table 2). These variables are likely to be correlated with the outcome, so in a properly matched cohort the imbalance would be averted. As expected, using PSM removes the imbalance in all selected variables. In comparison, the network-based matching removes most of the imbalance, except for ACE inhibitors and Cardiac arrhythmias ($p < 0.05$). Interestingly, the network-based matching introduces imbalance in the ‘history of cardiac arrhythmias’ variable. However, a slightly stricter level of significance ($p < 0.01$) would result in perfect balance.

We profiled the safety of cilostazol with respect to MACE, MALE and cardiac arrhythmia outcomes. We compared differences in outcomes (see Figure 1B) between the cilostazol group and control groups generated via PSM (green) and network-based patient-patient similarity clustering (blue) using logistic regression. The results show that in most outcome variables, PSM and network-based approach generate equivalent control groups.


Table 2: Balance in expert-selected variables before and after matching

Variable	Before Matching			Similarity network		PSM	
	Cilostazol (n= 223)	Control (n= 5534)	p-value*	Control (n= 223)	p-value	Control (n= 223)	p-value*
Demographics							
Age (at indication onset), mean (sd)	71.22 (11.02)	70.43 (12.46)	0.30	72.05 (10.62)	0.41	70.87 (11.51)	0.75
Gender (female), n (%)	37.22	45.94	<0.01	36.65	0.84	35.87	0.77
Race, (%)							
Asian	8.52	7.41	0.56	6.33	0.37	10.31	0.51
Black	2.69	3.71	0.36	3.61	0.59	0.90	0.16
Unknown	22.87	26.17	0.25	22.17	0.82	20.63	0.57
White	65.47	62.22	0.32	67.87	0.55	67.27	0.69
Comorbidities							
Coronary artery disease, n (%)	5.38	6.47	0.48	4.98	0.83	6.28	0.70
Congestive heart failure, n (%)	25.56	22.84	0.36	20.36	0.21	30.49	0.36
Hypertension, n (%)	10.76	11.31	0.80	9.50	0.75	10.31	0.88
Co-prescriptions							
Beta blocking agents, n (%)	75.34	60.77	<0.001	69.68	0.20	74.89	0.91
ACE inhibitors, plain, n (%)	78.03	69.57	<0.01	67.87	0.01	78.92	0.81
Platelet aggregation inhibitors excl. heparin, n (%)	91.93	79.00	<0.001	89.59	0.41	95.51	0.07
Vasodilators, n (%)	32.29	26.36	0.06	31.67	0.84	37.22	0.29
History of							
Cardiac arrhythmia, n (%)	32.29	32.17	0.97	23.08	0.03	33.18	0.84
Stroke, n (%)	17.94	18.31	0.89	15.84	0.61	21.52	0.34
Myocardial infarction, n (%)	17.94	15.87	0.43	13.58	0.24	19.73	0.64
Vascular surgical procedures, n (%)	74.44	47.71	< 0.001	65.61	0.05	74.44	1
Bypass procedures, n (%)	41.70	26.56	<0.001	36.20	0.24	40.36	0.75

*P-values are based on χ^2 -test for categorical, and two-sample t-test for continuous variables

Outcome analysis: To compare the outcomes in cilostazol patients with the controls using a network-based approach, we focused on those nodes and edges that are over- or under-represented in the cilostazol group. Figure 2 depicts the resulting network, nodes represent the clinical concepts, the edges their association strength. Nodes are colored according to their semantic group; node height corresponds to frequency in the cilostazol cohort, and node width to the frequency in the control. Cilostazol is therefore a thin and tall node. We colored the edges according to the over-representation in the two groups of patients. Red edges are over-represented in the cilostazol patients and blue edges in the control group. The thickness of the edges represents the statistical significance of the over-representation. Two main clusters are visible, in the upper right part there is a cluster of concepts over-represented in the cilostazol group, and in the lower left part are concepts over-represented in the control group. The cilostazol cluster contains different vascular surgical procedures (angioplasty, revascularization and bypass procedures) and some imaging procedures (ultrasonography, doppler and ultrasound imaging) used to diagnose PAD and to monitor

Figure 2: Concept-concept network, nodes represent clinical concepts and edges their associations in the clinical notes.



Moreover, we profiled differences in outcome between the cilostazol and the control groups and showed that both matching approaches, network-based and PSM produce similar results, confirming that both control groups are equivalent. Here, the main advantage of the network-based approach is that no expert-knowledge is required to identify potential confounders. In addition, we can use all concepts found in the patient's clinical notes to compute similarity between the patients in their phenotypic profiles. Others have also shown that a combination of features (in particular diseases, medications, findings and medical procedures) achieve better performance in classifying patients compared with restricting the features to one semantic group (such as diseases)²⁶.

We used a *concept-concept association network* to profile differences in outcome. In contrast to standard logistic regression analysis, which is restricted to those concepts considered meaningful by a medical expert, the network-based approach does not restrict the concept space. Using the networks as a tool for visualizing associations found in the clinical notes, we can analyze large numbers of concepts and their associations simultaneously as well as uncover the same results as regular methods would; as evidenced by the agreement with standard logistic regression analysis (Figure 1B) and confirmed by a medical expert. In contrast to standard clustering approaches, the use of networks allows for user-friendly visualization of the data, and the constructed networks can easily be enriched with additional information to guide the analysis. For example, the patient-patient similarity networks could be layered with the information about which concepts contributed most to the association between two patients, such that the researcher understands why a control is matched to a cilostazol patient, adding transparency to the analysis.

Limitations and future work: Automatically generated annotations of clinical notes can contain errors. However, with accuracies ranging from 86% for recognizing diseases, in particular 92% for identifying PAD, 93% for drugs and 97% for negations¹⁹, the annotation derived features are “good enough” for such a study. In contrast to logistic regression the concept-concept network does not provide a single score (such as an odds ratio) for each outcome variable. In future work, we want to use the concept-concept network to identify those variables worth being included in a standard outcome analysis and see if this selection agrees with expert choices. Moreover, we plan to compare different similarity metrics²⁶, and to investigate the use of bipartite networks similarly as previously described for analyzing associations of patients and SNPs²⁷ or cytokines²⁸.

Conclusion

Network-based approaches are applicable for constructing control groups as well as for analyzing clinical outcomes as shown by our case study on the safety of cilostazol in PAD patients. Our results show similar performance of the network-based approaches compared to standard methods used in comparative effectiveness research²⁹. One clear advantage of this approach is that the analysis is not limited to expert-selected variables, allowing the analysis of large numbers of variables and their associations simultaneously. In addition, visualizing associations between patients and concepts as networks allows for transparent interpretation.

Acknowledgements: ABM, PJL, RH and NHS acknowledge support from the NIH grant U54 HG004028 for the National Center for Biomedical Ontology.

the vascular surgical procedures²⁵; thus it is not surprising to find a strong association between these concepts in the clinical notes. In contrast, the control cluster is more heterogeneous and contains concepts related to severe heart failure, which is a contraindication for Cilostazol use.

Discussion

One key aspect of our work is the use of temporal ordering of clinical notes to group the annotations into concepts used for control group construction and concepts useful for outcome analysis. In particular, we used the annotations before the treatment (e.g., cilostazol) to construct a *patient-patient similarity network* from which we selected a matched control group. By analyzing the balance in expert-selected variables before and after matching, we showed that our network-based approach achieves similar performance compared to standard PSM.

References

1. Friedman C, Shagina L, Lussier Y, Hripcsak G. Automated encoding of clinical documents based on natural language processing. *J. Am. Med. Inform. Assoc.* Sep-Oct 2004;11(5):392-402.
2. Savova GK, Masanz JJ, Ogren PV, et al. Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation and applications. *J. Am. Med. Inform. Assoc.* 2010;17(5):507-513.
3. Shah NH, Bhatia N, Jonquet C, Rubin D, Chiang AP, Musen MA. Comparison of concept recognizers for building the Open Biomedical Annotator. *BMC Bioinformatics.* 2009;10 Suppl 9:S14.
4. Coloma PM, Schuemie MJ, Trifiro G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. *Pharmacoepidemiol Drug Saf.* 2011;20(1):1-11.
5. Haerian K, Varn D, Vaidya S, Ena L, Chase HS, Friedman C. Detection of pharmacovigilance-related adverse events using electronic health records and automated methods. *Clin. Pharmacol. Ther.* 2012;92(2):228-234.
6. Lependu P, Iyer SV, Fairon C, Shah NH. Annotation Analysis for Testing Drug Safety Signals using Unstructured Clinical Notes. *J Biomed Semantics.* 2012;3 Suppl 1:S5.
7. Lependu P, Liu Y, Iyer S, Udell MR, Shah NH. Analyzing patterns of drug use in clinical notes for patient safety. *AMIA Summits Transl Sci Proc.* 2012;2012:63-70.
8. Hripcsak G, Albers DJ, Perotte A. Exploiting time in electronic health record correlations. *J. Am. Med. Inform. Assoc.* Dec 2011;18 Suppl 1:i109-115.
9. Li Y, Salmasian H, Harpaz R, Chase H, Friedman C. Determining the reasons for medication prescriptions in the EHR using knowledge and natural language processing. *AMIA. Annu. Symp. Proc.* 2011;2011:768-776.
10. Lim J, Hao T, Shaw C, et al. A Protein-Protein Interaction Network for Human Inherited Ataxias and Disorders of Purkinje Cell Degeneration. *Cell.* 2006;125(4):801-814.
11. Przulj N, Wgle DA, Jurisica I. Functional topology in a network of protein interactions. *Bioinformatics.* 2004;20(3):340-348.
12. Hanauer DA, Rhodes DR, Chinnaiyan AM. Exploring Clinical Associations Using ‘-Omics’ Based Enrichment Analyses. *PLoS ONE.* 2009;4(4):e5203.
13. Roque FS, Jensen PB, Schmock H, et al. Using electronic patient records to discover disease correlations and stratify patient cohorts. *PLoS Comp. Biol.* Aug 2011;7(8):e1002141.
14. Park J, Lee D-S, Christakis NA, Barabasi A-L. The impact of cellular networks on disease comorbidity. *Mol. Syst. Biol.* 2009;5.
15. Bodenreider O, McCray AT. Exploring semantic groups through visual approaches. *J. Biomed. Inf.* 2003;36(6):414-432.
16. Xu R, Musen MA, Shah NH. A Comprehensive Analysis of Five Million UMLS Metathesaurus Terms Using Eighteen Million MEDLINE Citations. *AMIA. Annu. Symp. Proc.* 2010;2010:907-911.
17. Wu ST, Liu H, Li D, et al. Unified Medical Language System term occurrences in clinical notes: a large-scale corpus analysis. *J. Am. Med. Inform. Assoc.* 2012.
18. Gautam KP, Jonquet C, Xu R, Musen M, Shah NH. The Lexicon Builder Web service: Building Custom Lexicons from two hundred Biomedical Ontologies. *AMIA Annu. Symp. Pro.* 2010;2010:587.
19. Chapman WW, Chu D, Dowling JN. ConText: An Algorithm for Identifying Contextual Features from Clinical Text. Paper presented at: Workshop on BioNLP 2007: Biological, Translational, and Clinical Language Processing 2007.
20. Chapman WW, Bridewell W, Hanbury P, Cooper GF, Buchanan BG. A simple algorithm for identifying negated findings and diseases in discharge summaries. *J Biomed Inform.* Oct 2001;34(5):301-310.
21. LePendu P, Iyer SV, Bauer-Mehren A, Harpaz R, Mortensen JM, Shah NH. Pharmacovigilance using free-text clinical notes. *Under revision (Nature CPT).*
22. Sekhon JS. Multivariate and Propensity Score Matching Software with Automated Balance Optimization The Matching Package for R. *Journal of Statistical Software.* 2011;42(7).
23. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* 2003;13(11):2498-2504.
24. Chi YW, Lavie CJ, Milani RV, White CJ. Safety and efficacy of cilostazol in the management of intermittent claudication. *Vasc Health Risk Manag.* 2008;4(6):1197-1203.
25. Lumsden AB, Davies MG, Peden EK. Medical and endovascular management of critical limb ischemia. *J. Endovasc. Ther.* Apr 2009;16(2 Suppl 2):II31-62.
26. Cao H, Melton GB, Markatou M, Hripcsak G. Use abstracted patient-specific features to assist an information-theoretic measurement to assess similarity between medical cases. *J Biomed Inform.* Dec 2008;41(6):882-888.
27. Bhavnani SK, Bellala G, Victor S, Bassler KE, Visweswaran S. The role of complementary bipartite visual analytical representations in the analysis of SNPs: a case study in ancestral informative markers. *J. Am. Med. Inform. Assoc.* 2012;19(e1):e5-e12.
28. Bhavnani SK, Victor S, Calhoun WJ, et al. How cytokines co-occur across asthma patients: from bipartite network analysis to a molecular-based classification. *J. Biomed. Inf.* Dec 2011;44 Suppl 1:S24-30.
29. Sox HC, Goodman SN. The methods of comparative effectiveness research. *Annu.Rev.PublicHealth.* 2012;33:425-445.